Related references
Note: Only part of the references are listed.PACAP-38 and PACAP(6-38) Degranulate Rat Meningeal Mast Cells via the Orphan MrgB3-Receptor
Sara Hougaard Pedersen et al.
FRONTIERS IN CELLULAR NEUROSCIENCE (2019)
Exploration of purinergic receptors as potential anti-migraine targets using established pre-clinical migraine models
Kristian A. Haanes et al.
CEPHALALGIA (2019)
Pathophysiological Mechanisms in Migraine and the Identification of New Therapeutic Targets
Kristian Agmund Haanes et al.
CNS DRUGS (2019)
CSD-Induced Arterial Dilatation and Plasma Protein Extravasation Are Unaffected by Fremanezumab: Implications for CGRP's Role in Migraine with Aura
Aaron J. Schain et al.
JOURNAL OF NEUROSCIENCE (2019)
Opening of ATP-sensitive potassium channels causes migraine attacks: a new target for the treatment of migraine
Mohammad Al-Mahdi Al-Karagholi et al.
BRAIN (2019)
Hypothalamic regulation of headache and migraine
Arne May et al.
CEPHALALGIA (2019)
C-fibers may modulate adjacent Aδ-fibers through axon-axon CGRP signaling at nodes of Ranvier in the trigeminal system
Jacob C. A. Edvinsson et al.
JOURNAL OF HEADACHE AND PAIN (2019)
Pharmacologic Characterization of ALD1910, a Potent Humanized Monoclonal Antibody against the Pituitary Adenylate Cyclase-Activating Peptide
Cristina Moldovan Loomis et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2019)
CGRP as the target of new migraine therapies - successful translation from bench to clinic
Lars Edvinsson et al.
NATURE REVIEWS NEUROLOGY (2018)
Fremanezumab-A Humanized Monoclonal Anti-CGRP Antibody-Inhibits Thinly Myelinated (Aδ) But Not Unmyelinated (C) Meningeal Nociceptors
Agustin Melo-Carrillo et al.
JOURNAL OF NEUROSCIENCE (2017)
Human models of migraine - short-term pain for long-term gain
Messoud Ashina et al.
NATURE REVIEWS NEUROLOGY (2017)
Premonitory and nonheadache symptoms induced by CGRP and PACAP38 in patients with migraine
Song Guo et al.
PAIN (2016)
Inflammatory and neuropathic pain are rapidly suppressed by peripheral block of hyperpolarisation-activated cyclic nucleotide-gated ion channels
Gareth T. Young et al.
PAIN (2014)
Pituitary adenylate cyclase activating polypeptide and migraine
Alessandro S. Zagami et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2014)
Alterations in PACAP-38-like immunoreactivity in the plasma during ictal and interictal periods of migraine patients
Bernadett Tuka et al.
CEPHALALGIA (2013)
Comprehensive RNA-Seq Expression Analysis of Sensory Ganglia with a Focus on Ion Channels and GPCRs in Trigeminal Ganglia
Stavros Manteniotis et al.
PLOS ONE (2013)
Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR Review 1
Anthony J. Harmar et al.
BRITISH JOURNAL OF PHARMACOLOGY (2012)
HCN2 ion channels: an emerging role as the pacemakers of pain
Edward C. Emery et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2012)
SEX DIFFERENCES IN THE CONTRIBUTION OF ATP-SENSITIVE K+ CHANNELS IN TRIGEMINAL GANGLIA UNDER AN ACUTE MUSCLE PAIN CONDITION
K. Niu et al.
NEUROSCIENCE (2011)
Vasoactive intestinal peptide causes marked cephalic vasodilation, but does not induce migraine
A. Rahmann et al.
CEPHALALGIA (2008)
Role of the hyperpolarization-activated current Ih in somatosensory neurons
Aliakmal Momin et al.
JOURNAL OF PHYSIOLOGY-LONDON (2008)
Vasoactive intestinal polypeptide evokes only a minimal headache in healthy volunteers
J. M. Hansen et al.
CEPHALALGIA (2006)
Hyperpolarization-activated, cyclic nucleotide-gated cation channels: Roles in the differential electrophysiological properties of rat primary afferent neurons
HY Tu et al.
JOURNAL OF NEUROSCIENCE RESEARCH (2004)
Potassium channels and pain:: present realities and future opportunities
M Ocaña et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2004)
Share Paper
